Optimer Pharmaceuticals Inc: (NASD: OPTR)
$14.67
0.29 (2.02%)
Volume 558,359
May 23 04:00 PM ET
Zacks Rank: 4-Sell 
| #4 |
Overview Quote
Stock Activity
| Day Low - High | 14.05 - 14.68 |
| 52wk Low - High | 8.64 - 16.80 |
| Previous Close | 14.38 |
| Avg. Volume | 1,358,340 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 688.82 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.46 |
| PE (Forward) | 0.00 |
| Current Year Est. | -2.17 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 4 |
Zacks Recommendation
|
Underperform |
Zacks Industry Rank
|
95 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.17 |
| Current Quarter Estimate | -0.60 |
| Most Accurate Estimate | -0.60 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -1.62 |
| Expected Earnings Growth | 3.00% |
Company Description
OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.60 | -0.50 | -2.17 | -1.07 |
| Number of Estimates | 7 | 6 | 9 | 8 |
| Low Estimate | -0.69 | -0.58 | -2.38 | -1.43 |
| High Estimate | -0.52 | -0.42 | -1.95 | NA |
| Year Ago EPS | -0.01 | -0.56 | -1.51 | -2.17 |
| EPS Growth | -5,871.43% | 10.12% | -43.64% | 50.49% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| OPTIMER PHARMAC | OPTR | 14.38 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 13.75 | |
|
| GENTIUM SPA-ADR | GENT | 8.79 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACADIA PHARMA | ACAD | 13.42 | |
|
| ACHILLION PHARM | ACHN | 7.74 | |
|
| ADDEX THERA LTD | ADDXF | 6.62 | |
|
| AFFYMAX INC | AFFY | 1.40 | |
|
| ALEXION PHARMA | ALXN | 100.57 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Wider-than-Expected Loss at Optimer
May 10, 2013
The Zacks Analyst Blog Highlights: AT&T, Optimer Pharmaceuticals, ViroPharma, Astellas Pharma and Incyte
May 02, 2013
Optimer's Dificid Cleared Down Under
May 01, 2013
1Q Earnings Beat at Cubist Pharma
Apr 19, 2013
Will Cubist Pharma Beat Earnings?
Apr 16, 2013
Optimer Posts Wider Loss
Mar 04, 2013
Encouraging News for Cubist Pharma
Mar 01, 2013
Cubist Pharma Inks Deal
Feb 26, 2013
Financials
| EPS TTM | -1.62 |
| Sales | 102 |
| Net Income | -57 |
| Price/Earnings | NA |
| Price/Book | 6.55 |
| Price/Cash Flow | NA |
| Price/Sales | 6.46 |
News
2 Biotechs to Avoid, 1 to Buy - TheMotleyFool
May 23, 2013
Optimer Pharmaceuticals Q1 net loss increases - Datamonitor
May 23, 2013
Cubist, Optimer, Trius: Antibiotic Deal Making On Tap - TheStreet.com
May 22, 2013
Shares of Optimer Pharmaceuticals Receive a Boost, Up 1.5% - Financial News Network Online - Market Movers
May 22, 2013
Optimer Pharmaceuticals Earnings In Retrospect: Up 0.3% in the Last 11 Days (OPTR) - Comtex Smartrend(R)
May 20, 2013
Optimer Pharmaceuticals Earnings Hindsight: Up 0.3% in Last 9 Days (OPTR) - Financial News Network Online - Earnings Lookback
May 18, 2013
Buyers Accumulate Shares of Optimer Pharmaceuticals, Up 1.8% - Financial News Network Online - Market Movers
May 17, 2013
Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards - Benzinga
May 16, 2013
Broker Recommendations
| Current ABR | 2.48 |
| ABR (Last Week) | 2.48 |
| # of recs in ABR | 11 |
| Average Target Price | 17.25 |
| Industry Rank by ABR | 95 out of 265 |
| Rank in Industry | 132 out of 152 |
